“The work represents another important milestone, however, challenges remain,” says University of Wisconsin stem cell biologist James Thomson, by e-mail. “The most important criteria for choosing a particular reprogramming approach will be whether one can derive an (induced pluripotent stem) cell line from an easily obtained clinical sample consistently, and whether the resulting (induced pluripotent) cell line has a normal genetic and epigenetic (gene activation) status. It is not yet clear what approach, or combination of approaches, will most consistently meet these criteria.”
(Second item from beginning.)
Office of Strategic Communication